Early Cancer Detection Test, Ccheck, May Reduce Number of Unnecessary Prostate Biopsies, Anixa Says

Early Cancer Detection Test, Ccheck, May Reduce Number of Unnecessary Prostate Biopsies, Anixa Says
Ccheck, a new test for early cancer detection under development by Anixa Biosciences, was able to identify patients with aggressive prostate cancer, and helped decide who should be recommended for a prostate biopsy, potentially reducing the number of unnecessary biopsies, the company announced. The test may be also used for other cancer types in the future. The early findings are from an ongoing study validating Ccheck for prostate cancer screening and were presented at the 2019 American Association of Cancer Research Annual Meeting, held March 29–April 3 in Atlanta. The presentation, “Using machine learning to predict the risk of either having an aggressive form of prostate cancer (PCa) or lower-grade PCa/benign prostatic hyperplasia (BPH) based upon the flow cytometry immunophenotyping of myeloid-derived suppressor cells (MDSCs) and lymphocyte cell populations,” is available here. Anixa’s ongoing study is evaluating if Ccheck can accurately predict if a man is at higher risk of having an aggressive form of prostate cancer (Gleason grade 4+3 or higher) — and should be recommended for biopsy — or if he is at lower or no risk for the cancer. The prostate-specific antigen (PSA) test is the standard for detecting prostate cancer but “results in a large frequency of false positives leading to numerous men each year undergoing unnecessary prostate biopsy procedures,” the researchers said in their presentation. Ccheck detects a type of cell that often appears early in cancer, called myeloid-derived suppressor cells (MDSCs), by combining flow cytometry — a technique that detects specific cell populations within a biological sample — and artificial intelligence (machine learning). MDSCs are often induced by tumors of different types, af
Subscribe or to access all post and page content.